The development of payload resistant cell lines to study antibody-drug conjugate resistance in high-grade serous ovarian cancer

Abstract Antibody-drug conjugates (ADCs) are increasingly used to treat recurrent high grade serous ovarian cancer (HGSOC), yet their effects on tumor biology and subsequent treatment response remain poorly understood. We evaluated the short-term effects of ADCs and their respective payloads on ADC receptor expression and developed payload resistant HGSOC cell lines to determine how acquired payload resistance influences response to subsequent ADC therapy. Matched platinum sensitive and resistant HGSOC cell lines were exposed to trastuzumab deruxtecan (T-DXd) and mirvetuximab soravtansine (MIRV), or their respective payloads, DXd and DM4. DXd and DM4 resistant cell lines were generated through sequential payload dose escalation and characterized for ADC receptor expression and response to T-DXd, MIRV, and sacituzumab govitecan (SG). Short-term T-DXd and MIRV exposure reduced their respective targets in chemosensitive cells and altered several clinically relevant ADC receptors. DXd and DM4 resistant cell lines were developed and confirmed resistant. Notably, DM4 resistant cells showed increased T-DXd sensitivity, whereas DXd resistant cells exhibited reduced sensitivity to MIRV and SG. These findings demonstrate that ADC exposure dynamically alters receptor expression and that acquired payload resistance can differentially influence subsequent ADC response. Further investigation may identify biomarkers of ADC resistance and inform upon ADC sequencing strategies in HGSOC.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11269110/v1
Primary Topic
Ovarian cancer diagnosis and treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

The development of payload resistant cell lines to study antibody-drug conjugate resistance in high-grade serous ovarian cancer

Areta Bojko, Payton De La Cruz, Angelica Salaverria, Samantha Buyungo et al.
8 links
Research Square
Ovarian cancer diagnosis and treatment
preprint

The development of payload resistant cell lines to study antibody-drug conjugate resistance in high-grade serous ovarian cancer

Areta Bojko, Payton De La Cruz, Angelica Salaverria, Samantha Buyungo, Cara Mathews, Paul Disilvestro, Janina Vaitkus Pearce, Nicole E. James
preprint en

Abstract

Abstract Antibody-drug conjugates (ADCs) are increasingly used to treat recurrent high grade serous ovarian cancer (HGSOC), yet their effects on tumor biology and subsequent treatment response remain poorly understood. We evaluated the short-term effects of ADCs and their respective payloads on ADC receptor expression and developed payload resistant HGSOC cell lines to determine how acquired payload resistance influences response to subsequent ADC therapy. Matched platinum sensitive and resistant HGSOC cell lines were exposed to trastuzumab deruxtecan (T-DXd) and mirvetuximab soravtansine (MIRV), or their respective payloads, DXd and DM4. DXd and DM4 resistant cell lines were generated through sequential payload dose escalation and characterized for ADC receptor expression and response to T-DXd, MIRV, and sacituzumab govitecan (SG). Short-term T-DXd and MIRV exposure reduced their respective targets in chemosensitive cells and altered several clinically relevant ADC receptors. DXd and DM4 resistant cell lines were developed and confirmed resistant. Notably, DM4 resistant cells showed increased T-DXd sensitivity, whereas DXd resistant cells exhibited reduced sensitivity to MIRV and SG. These findings demonstrate that ADC exposure dynamically alters receptor expression and that acquired payload resistance can differentially influence subsequent ADC response. Further investigation may identify biomarkers of ADC resistance and inform upon ADC sequencing strategies in HGSOC.

Research Square
Brown University (US)
Swim Across America
Good health and well-being
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon